Anatomic stage iii breast cancer ajcc v8 Trials in Springfield, United States
Conditions / Anatomic stage iii breast cancer ajcc v8 / Springfield, United States
Clinical trials for Anatomic stage iii breast cancer ajcc v8 investigate a range of treatment strategies and patient populations.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING | — |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | RECRUITING | — |